Can extra rituximab keep vasculitis at bay?
NCT ID NCT02433522
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether giving rituximab for 46 months instead of the usual 18 months can better prevent relapses of ANCA-associated vasculitis, a rare autoimmune disease that causes blood vessel inflammation. 97 patients who were already in remission after initial rituximab treatment were randomly assigned to receive either additional rituximab infusions or a placebo. The goal was to see if the longer treatment keeps patients relapse-free for longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab
- What this could lead to
- If successful, this could show that longer rituximab treatment helps prevent disease relapses in people with ANCA-associated vasculitis.
- What could go wrong
- This is a small, completed Phase 3 trial with only 97 participants. Results may not apply to all patients, and longer treatment could increase infection risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIDES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital cochin
Paris, 75014, France